Five Ways Pharma is Leveraging Digital Therapeutics to Demonstrate Value to Health Plans

Some estimates now put the cost of developing a new drug at nearly $2.9 billion. Adding to this financial pressure, pharmaceutical companies have little control over what CMS, health plans and PBMs will agree to pay for approved drugs, or if their new drugs will be listed on formularies—often because the value of new drugs is still an unknown. To overcome some of these challenges, pharma companies are increasingly leveraging digital therapeutics in tandem with pharmacotherapy to optimize the therapy and to efficiently collect  real-world evidence of efficacy, outcomes and ROI—as well as data on adherence and quality of life. This approach helps prove value for better reimbursements and formulary inclusion in an emerging value-driven environment.